Open an account

Exact Sciences

EXAS · NASDAQ

Price unavailable right now.

No price history for this range.

About EXAS

Exact Sciences offers a portfolio of cancer screening and diagnostic tests that cover early detection through post-treatment monitoring. The company is headquartered in Madison, Wisconsin and currently employs 7,100 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Employees
7,100
Headquarters
Madison, Wisconsin
Listed
Jan 30, 2001
Sector
Health Care
Industry
Biotechnology
Website
exactsciences.com

EXAS key statistics

This section is temporarily unavailable. Refresh to try again.

Analyst ratings

Latest rating from each analyst over the past 12 months

23%of 13 analyst ratings say Buy
  • Buy23.1%
  • Hold76.9%
  • Sell0.0%
Price target · 13 analystsAvg $104.35
Low
$78.78
High
$110.25

EXAS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 56.0% on average.

  1. Q1 FY24: reported -$0.60 per share against an estimate of -$0.4743
  2. Q2 FY24: reported -$0.09 per share against an estimate of -$0.3284
  3. Q3 FY24: reported -$0.21 per share against an estimate of -$0.212
  4. Q4 FY24: reported -$4.67 per share against an estimate of -$0.313
  5. Q1 FY25: reported -$0.54 per share against an estimate of -$0.3883
  6. Q2 FY25: reported -$0.01 per share against an estimate of -$0.1828
  7. Q3 FY25: reported -$0.10 per share against an estimate of -$0.0714
  8. Q4 FY25: reported -$0.38 per share against an estimate of -$0.0676

EXAS news

  • Press releaseBusiness Wire

    Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

  • Press releaseBusiness Wire

    Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

  • Press releaseBusiness Wire

    Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration

  • Press releaseBusiness Wire

    Exact Sciences Stockholders Approve Acquisition by Abbott

  • Press releaseBusiness Wire

    Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results

  • Press releaseBusiness Wire

    Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests

  • Press releaseBusiness Wire

    Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS

Similar companies

Companies in the same industry as Exact Sciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.